Stem cell research has progressed to the point where up to six products
for adult treatments could be on the market in as soon as two years,
including one from Ann Arbor-based
Aastrom.
Excerpt:
Aastrom, formed in 1991, takes bone marrow collected from patients by
their doctors, processes it, then mails back the stem cells to be
reintroduced into the patient's body at fracture sites. The company's
method was developed by researchers at the University of Michigan in
Ann Arbor. Its process manipulates and expands the cells, so extensive
testing will be required to obtain FDA approval.
Aastrom is
also conducting trials that use stem cells in spinal fusion, jawbone
reconstruction and a rare disease, osteonecrosis, which often requires
repeated hip replacements.
The company plans to begin final-stage trials for osteonecrosis in the first half of this year.
Read the entire article
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.